RUNX3 and lymphoma: We also noted that the RUNX3 expression increased in 13 tumors (breast, cervical, esophageal, gastric, head and neck, kidney, leukemia, liver, lymphoma, melanoma, ovarian, pancreatic, and sarcoma cancers) and decreased in 4 tumors (bladder, colorectal, leukemia, and lymphoma cancers) relative to that in the normal tissues (Figure 1A, right panel).